Pharmaceutical company Boehringer Ingelheim has shown stronger growth than the world pharmaceutical market for the ninth year in a row. Announcing its annual figures, the company’s net sales rose to €11.6 billion (2007 €10.9 billion). This corresponds to an increase of +9.5% and +5.9%.
The animal health business contributed to the company’s growth figures. With an increase in net sales of +19.5% and +14.4% to €467 million, Boehringer Ingelheim claims to be the fastest growing company of the ten largest companies in the field of veterinary medicine. The growth driver was the swine vaccine Ingelvac CircoFlex®, with an increase in net sales by more than 140% to some €90 million.
Board member Hubertus von Baumbach said: “Boehringer Ingelheim is running a successfully expanding and competitive business in the field of Animal Health. Through high investment in productive research we also see here further potential for success in the future.“
Total operating income
In a press release, the company said that total operating income, comparable to EBIT, was again at the planned level, and, at almost €2 billion, produced financially sound profitability comparable to the previous year. Operating income as a percentage of sales was 17.1% in 2008. At €1.4 billion, income after taxes stood at a similarly high level to that of the previous year, excluding one-off effects in 2007.
The company also increased its investments in the future. Expenditure for research and development rose by €200 million, or +11%, against the previous year. In total, the company spent €2.1 billion, substantially in the area of prescription medicines.
• Boehringer Ingelheim